Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon C Jayson

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 9, 2005
Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeuticsRuth Board, Gordon C Jayson
The Oncologist|February 15, 2005
Molecular imaging of antiangiogenic agentsShazza Rehman, Gordon C Jayson
Expert Opinion on Biological Therapy|February 26, 2008
Oligosaccharides as anti-angiogenic agentsClaire Louise Cole, Gordon C Jayson
Thescientificworldjournal|March 31, 2005
Profiling heparan sulfate proteoglycans in ovarian carcinomaAndrew R Clamp, Gordon C Jayson
Current Opinion in Oncology|August 15, 2013
Angiogenesis as a target for the treatment of ovarian cancerDanielle Shaw, Andrew Clamp, Gordon C Jayson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?James P B O'Connor, Gordon C Jayson
Expert Opinion on Drug Metabolism & Toxicology|January 31, 2012
Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapyLaura Horsley, Kalena Marti, Gordon C Jayson
Expert Opinion on Therapeutic Targets|November 16, 2006
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesisSofia Baka, Andrew R Clamp, Gordon C Jayson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
The best guess approach to phase I trial designDaniela D Rosa, John Harris, Gordon C Jayson
Clinical Medicine (London, England)|August 30, 2008
Angiogenesis as a therapeutic target in cancerGireesh Kumaran, Andrew R Clamp, Gordon C Jayson
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 9, 2005
Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeuticsRuth Board, Gordon C Jayson
The Oncologist|February 15, 2005
Molecular imaging of antiangiogenic agentsShazza Rehman, Gordon C Jayson
Expert Opinion on Biological Therapy|February 26, 2008
Oligosaccharides as anti-angiogenic agentsClaire Louise Cole, Gordon C Jayson
Thescientificworldjournal|March 31, 2005
Profiling heparan sulfate proteoglycans in ovarian carcinomaAndrew R Clamp, Gordon C Jayson
Current Opinion in Oncology|August 15, 2013
Angiogenesis as a target for the treatment of ovarian cancerDanielle Shaw, Andrew Clamp, Gordon C Jayson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?James P B O'Connor, Gordon C Jayson
Expert Opinion on Drug Metabolism & Toxicology|January 31, 2012
Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapyLaura Horsley, Kalena Marti, Gordon C Jayson
Expert Opinion on Therapeutic Targets|November 16, 2006
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesisSofia Baka, Andrew R Clamp, Gordon C Jayson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
The best guess approach to phase I trial designDaniela D Rosa, John Harris, Gordon C Jayson
Clinical Medicine (London, England)|August 30, 2008
Angiogenesis as a therapeutic target in cancerGireesh Kumaran, Andrew R Clamp, Gordon C Jayson
Pageof 13